SLC5A2 and hepatocellular carcinoma: In vitro studies, assessing the potential anticancer action of SGLT-2 inhibitors in relation to HCC, have shown that canagliflozin blocks the translocation of β-catenin from the cytoplasm to the cell nucleus.